×
About 8,793 results

ALLMedicine™ Anaphylaxis Center

Research & Reviews  2,623 results

COVID-19 vaccine anaphylaxis: IgE, complement or what else? A reply to: "COVID-19 vaccine anaphylaxis: PEG or not?"
https://europepmc.org/article/pmc/pmc8441702
Allergy Cabanillas B, Akdis CA et. al.

Jun 21st, 2021 - Thank you for the correspondence of Krantz et al “COVID‐19 vaccine anaphylaxis: PEG or not?”.1 We totally agree with the authors that patients previously allergic to polyethylene glycol (PEG) might react to PEGylated liposomes when exposed to t...

Case report: Acute exacerbation of interstitial pneumonia related to mRNA COVID-19 vacc...
https://doi.org/10.1016/j.ijid.2022.01.031
International Journal of Infectious Diseases : IJID : Off... Amiya S, Fujimoto J et. al.

Jan 23rd, 2022 - mRNA vaccines that protect against coronavirus disease (COVID-19) are widely used in many countries due to their high efficacy and safety profiles. Recently, some severe adverse events, such as anaphylaxis and myocarditis, were reported in healthy...

Pfizer/BioNtech BNT162b2: adverse events and insights from an Australian mass vaccinati...
https://doi.org/10.1111/imj.15623
Internal Medicine Journal; Halder A, Imamura H et. al.

Jan 22nd, 2022 - The Pfizer/BioNtech BNT162b2 is a major vaccine used in the Australian COVID-19 immunisation programme. We report on BNT162b2 safety in the observation period in a dedicated vaccination clinic linked to a quaternary teaching hospital. We performed...

Safely Reducing Hospitalizations for Anaphylaxis in Children Through an Evidence-Based ...
https://doi.org/10.1542/peds.2020-045831
Pediatrics Gaffney LK, Porter J et. al.

Jan 22nd, 2022 - Emergency department visits for anaphylaxis have increased considerably over the past few decades, especially among children. Despite this, anaphylaxis management remains highly variable and contributes to significant health care spending. On the ...

VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Subjects With Underlying Disease at High-risk for Worsening COVID-19
https://clinicaltrials.gov/ct2/show/NCT05084755

Jan 20th, 2022 - To provide more information on safety profile of VAXZEVRIA in Japanese subjects, specific drug use result study in subjects with underling disease at higher risk of worsening COVID-19 is planned as an additional pharmacovigilance plan. The present...

see more →

Guidelines  14 results

COVID-19 vaccine anaphylaxis: IgE, complement or what else? A reply to: "COVID-19 vaccine anaphylaxis: PEG or not?"
https://europepmc.org/article/pmc/pmc8441702
Allergy Cabanillas B, Akdis CA et. al.

Jun 21st, 2021 - Thank you for the correspondence of Krantz et al “COVID‐19 vaccine anaphylaxis: PEG or not?”.1 We totally agree with the authors that patients previously allergic to polyethylene glycol (PEG) might react to PEGylated liposomes when exposed to t...

Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practic...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802368
MMWR. Recommendations and Reports : Morbidity and Mortali... Choi MJ, Cossaboom CM et. al.

Jan 9th, 2021 - This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the rVSVΔG-ZEBOV-GP Ebola vaccine (Ervebo) in the United States. The vaccine contains rice-derived recombinant human serum albumin and...

STAT: Anaphylaxis.
https://doi.org/10.1188/20.CJON.336
Clinical Journal of Oncology Nursing;

May 23rd, 2020 - Anaphylaxis is a severe, potentially life-threatening acute allergic reaction that involves more than one system of the body.

AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (M...
https://doi.org/10.1016/j.jaci.2019.08.023
The Journal of Allergy and Clinical Immunology; Weiler CR, Austen KF et. al.

Sep 3rd, 2019 - Our current recommendations for diagnosing and treating primary mast cell (MC) activation syndrome make use of the latest studies and consensus guidelines for clinically recognizing systemic anaphylaxis in real time, regardless of whether allergen...

Guideline review: Epinephrine use in anaphylaxis (AAP guideline 2017).
https://doi.org/10.1136/archdischild-2017-314592
Archives of Disease in Childhood. Education and Practice ... Goodall N

Nov 18th, 2018 - Guideline review: Epinephrine use in anaphylaxis (AAP guideline 2017).|2018|Goodall N,|drug therapy,therapeutic use,therapeutic use,

see more →

Drugs  309 results see all →

Clinicaltrials.gov  73 results

COVID-19 vaccine anaphylaxis: IgE, complement or what else? A reply to: "COVID-19 vaccine anaphylaxis: PEG or not?"
https://europepmc.org/article/pmc/pmc8441702
Allergy Cabanillas B, Akdis CA et. al.

Jun 21st, 2021 - Thank you for the correspondence of Krantz et al “COVID‐19 vaccine anaphylaxis: PEG or not?”.1 We totally agree with the authors that patients previously allergic to polyethylene glycol (PEG) might react to PEGylated liposomes when exposed to t...

VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Subjects With Underlying Disease at High-risk for Worsening COVID-19
https://clinicaltrials.gov/ct2/show/NCT05084755

Jan 20th, 2022 - To provide more information on safety profile of VAXZEVRIA in Japanese subjects, specific drug use result study in subjects with underling disease at higher risk of worsening COVID-19 is planned as an additional pharmacovigilance plan. The present...

Sugammadex and Decreased Time to Extubation
https://clinicaltrials.gov/ct2/show/NCT03196167

Jan 14th, 2022 - Primary Efficacy Objective: To demonstrate faster time to extubation after arrival in the cardiothoracic ICU in patients having a CABG who receive Sugammadex 2mg/kg as compared to placebo. Hypotheses: We hypothesize that the use of Sugammadex for ...

POHCA Resuscitation: Evaluation of IM Epinephrine
https://clinicaltrials.gov/ct2/show/NCT05166343

Dec 21st, 2021 - IM epinephrine may provide a more efficient means of administering the initial epinephrine dose (versus IV/IO administration) to a child experiencing pediatric out of hospital cardiac arrest (POHCA) with no greater risk of harm. In so doing, this ...

CINERGY Pilot Trial
https://clinicaltrials.gov/ct2/show/NCT05148715

Dec 8th, 2021 - Background: Organ donation saves lives, and improves quality of life for thousands of people. But organ donation falls short of expectations for some patients who suffer early graft loss. During organ donation surgery, the supply of blood with oxy...

see more →

News  473 results

COVID-19 vaccine anaphylaxis: IgE, complement or what else? A reply to: "COVID-19 vaccine anaphylaxis: PEG or not?"
https://europepmc.org/article/pmc/pmc8441702
Allergy Cabanillas B, Akdis CA et. al.

Jun 21st, 2021 - Thank you for the correspondence of Krantz et al “COVID‐19 vaccine anaphylaxis: PEG or not?”.1 We totally agree with the authors that patients previously allergic to polyethylene glycol (PEG) might react to PEGylated liposomes when exposed to t...

Clear Food Labels Needed for People Allergic to Sesame
https://www.medscape.com/viewarticle/965855

Jan 3rd, 2022 - Among people who reported an allergic reaction to sesame in a survey, more than half (56%) of the triggering foods did not declare sesame on the label. The findings were published online last month in Annals of Allergy, Asthma and Immunology. Some...

25-year-old woman • abdominal pain • urticarial rash • recent influenza immunization • Dx?
https://www.mdedge.com/familymedicine/article/249695/immunology
MDedge Family Medicine; Danielle Yee, MD, Adam Skrynski, MD et. al.

Dec 8th, 2021 - THE CASE A 25-year-old woman presented to an infectious diseases (ID) physician with a 4-day history of symptoms following receipt of a quadrivalent influenza vaccine. Two hours after receiving the vaccine, the patient experienced abdominal pain.

Antibody Combo Gets EUA to Prevent COVID in Vulnerable Groups
https://www.medpagetoday.com/infectiousdisease/covid19/96088

Dec 8th, 2021 - The FDA authorized a long-acting monoclonal antibody combination, tixagevimab-cilgavimab (Evusheld), to prevent COVID-19 in immunocompromised individuals and those with a history of a severe vaccine reaction, the agency said on Wednesday. In its e...

New COVID-19 Vaccine Shows Good Efficacy and Toxicity Profile
https://www.medscape.com/viewarticle/963231

Nov 18th, 2021 - A randomised, double-blind, placebo-controlled, multicentre, phase 3 clinical trial has found that a new SARS-CoV-2 vaccine is “highly efficacious against laboratory-confirmed symptomatic COVID-19 disease”. Covaxin (code-named BBV152) is a whole v...

see more →

Patient Education  25 results see all →